Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
teACH: Navepegritide in Adolescents With Achondroplasia
2024-514208-15-00Phase 2Authorised
- Sponsor
- Ascendis Pharma
- Start
- Dec 2024
- Modality
- Peptides, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in achondroplasia (ACH) comparing Navepegritide (TransCon CNP) with Placebo for TransCon CNP (2 arms). Primary endpoint: Annualized growth velocity at Week 52. Planned start Dec 2024; status: authorised.
02
Drugs
navepegritide
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on 2024-514208-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514208-15-00.